| Levosulpiride | |
|---|---|
|
N-[[(2S)-1-Ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamide |
|
| Identifiers | |
| CAS number | 23672-07-3 |
| PubChem | 688272 |
| KEGG | D07312 |
| ChEMBL | CHEMBL267044 |
| Jmol-3D images | Image 1 |
|
|
| Properties | |
| Molecular formula | C15H23N3O4S |
| Molar mass | 341.43 g/mol |
| (verify) (what is: /?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
A substituted benzamide anti-psychotic, reported to be a selective antagonist of dopamine D2 receptors activity on both central and peripheral levels.It is an atypical neuroleptic and a prokinetic agent. Levosulpiride is also claimed to have mood elevating properties. Levosulpiride is used in the treatment of psychoses, particularly negative symptoms of schizophrenia, anxiety disorders, dysthymia, vertigo, dyspepsia, irritable bowel syndrome and premature ejaculation.
In a dose range of 25-200 mg/day in divided doses, Levosulpiride is therapeutic for negative and cognitive symptoms of schizophrenia, and for depressive and somatoform disorders.
Levosulpiride is an antipsychotic and prokinetic agent. It is the (S)-enantiomer of sulpiride.
It is sold in Spain under the brand name Levogastrol.
Levosulpiride Adverse Reactions / Levosulpiride Side Effects
Amenorrhoea, gynaecomastia, galactorrhoea, changes in libido.
Potentially Fatal: Neuroleptic malignant syndrome.
Special Precautions
May impair ability to drive or operate machinery. Pregnancy and lactation. Other Drug Interactions
Reduced bioavailability with sucralfate, aluminium- and magnesium-containing antacids. Effect on GI motility may be antagonised by anticholinergic agents, narcotics and analgesics. Avoid alcohol.